國立虎尾科技大學 |

Applications of FDG PET in Oncology = Best Clinical Practice /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Applications of FDG PET in Oncology/ edited by Hirofumi Fujii, Hiroyuki Nakamura, Seiei Yasuda.
其他題名:	Best Clinical Practice /
其他作者:	Yasuda, Seiei.
面頁冊數:	VII, 147 p. 61 illus., 55 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer Research. -
電子資源:	https://doi.org/10.1007/978-981-15-8423-7
ISBN:	9789811584237

Applications of FDG PET in Oncology = Best Clinical Practice /
Applications of FDG PET in OncologyBest Clinical Practice /[electronic resource] :edited by Hirofumi Fujii, Hiroyuki Nakamura, Seiei Yasuda. - 1st ed. 2021. - VII, 147 p. 61 illus., 55 illus. in color.online resource.

1 Overview.-2 Lung cancer.-3 Breast cancer -- 4 Head and neck cancer.-5 Gastrointestinal cancer including GIST -- 6 Pancreatic cancer -- 7 Urological cancer -- 8 Malignant bone and soft tissue tumors -- 9 Skin cancer including malignant melanoma -- 10 Malignant lymphoma.

This book provides up-to-date guidance on the use of FDG PET to assess the biological activity and treatment response of a wide range of malignancies, including, for example, lung cancer, breast cancer, head and neck cancer, gastrointestinal cancer, and malignant lymphoma. In the era of precision medicine, numerous new anticancer agents, such as molecular targeted agents and immune checkpoint inhibitors, have been developed to improve outcomes in cancer patients. FDG PET plays a key role in evaluating the effects of these novel treatments because it can detect changes in the metabolic activity of tumors before any reduction in their size is visible on other imaging modalities. Accordingly, FDG PET is of prognostic as well as diagnostic value, and allows prompt changes in patient management. The book is written by expert clinicians from Japan, where the universal public health insurance system ensures that FDG PET is widely used in routine oncological practice and cancer screening. It represents an unrivaled and comprehensive resource that will be of value for all healthcare professionals in the field of clinical oncology.

ISBN: 9789811584237

Standard No.: 10.1007/978-981-15-8423-7doiSubjects--Topical Terms:

668358
Cancer Research.

LC Class. No.: RC254-282

Dewey Class. No.: 616.994

Applications of FDG PET in Oncology = Best Clinical Practice /
LDR:02776nam a22003975i 4500 001 1050399
003 DE-He213
005 20210619185358.0
007 cr nn 008mamaa
008 220103s2021 si | s |||| 0|eng d
020 $a 9789811584237 $9 978-981-15-8423-7
024 7 $a 10.1007/978-981-15-8423-7 $2 doi
035 $a 978-981-15-8423-7
050 4 $a RC254-282
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
245 1 0 $a Applications of FDG PET in Oncology $h [electronic resource] : $b Best Clinical Practice / $c edited by Hirofumi Fujii, Hiroyuki Nakamura, Seiei Yasuda.
250 $a 1st ed. 2021.
264 1 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2021.
300 $a VII, 147 p. 61 illus., 55 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a 1 Overview.-2 Lung cancer.-3 Breast cancer -- 4 Head and neck cancer.-5 Gastrointestinal cancer including GIST -- 6 Pancreatic cancer -- 7 Urological cancer -- 8 Malignant bone and soft tissue tumors -- 9 Skin cancer including malignant melanoma -- 10 Malignant lymphoma.
520 $a This book provides up-to-date guidance on the use of FDG PET to assess the biological activity and treatment response of a wide range of malignancies, including, for example, lung cancer, breast cancer, head and neck cancer, gastrointestinal cancer, and malignant lymphoma. In the era of precision medicine, numerous new anticancer agents, such as molecular targeted agents and immune checkpoint inhibitors, have been developed to improve outcomes in cancer patients. FDG PET plays a key role in evaluating the effects of these novel treatments because it can detect changes in the metabolic activity of tumors before any reduction in their size is visible on other imaging modalities. Accordingly, FDG PET is of prognostic as well as diagnostic value, and allows prompt changes in patient management. The book is written by expert clinicians from Japan, where the universal public health insurance system ensures that FDG PET is widely used in routine oncological practice and cancer screening. It represents an unrivaled and comprehensive resource that will be of value for all healthcare professionals in the field of clinical oncology.
650 2 4 $a Cancer Research. $3 668358
650 2 4 $a Imaging / Radiology. $3 669876
650 1 4 $a Oncology. $3 593951
650 0 $a Cancer research. $3 1253664
650 0 $a Radiology. $3 673943
650 0 $a Oncology . $3 1253469
700 1 $a Yasuda, Seiei. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1354705
700 1 $a Nakamura, Hiroyuki. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1103255
700 1 $a Fujii, Hirofumi. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1354704
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9789811584220
776 0 8 $i Printed edition: $z 9789811584244
776 0 8 $i Printed edition: $z 9789811584251
856 4 0 $u https://doi.org/10.1007/978-981-15-8423-7
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)